Brokerage firm Leerink Swann Upgrades its rating on Illumina(ILMN). The shares have been rated Outperform. Previously, the analysts had a Market Perform rating on the shares. The rating by the stock financial advisor at Leerink Swann was issued on Mar 20, 2017 in a research report to their Investors and Clients.
In a different note, On Feb 27, 2017, Evercore ISI Group said it Upgrades its rating on Illumina. The shares have been rated ‘Buy’ by the firm. Deutsche Bank said it Initiates Coverage On Illumina, according to a research note issued on Jan 18, 2017. In the research note, the firm Announces the price-target to $160 per share. The shares have been rated ‘Hold’ by the firm.
Illumina (ILMN) made into the market gainers list on Wednesdays trading session with the shares advancing 2.62% or 4.29 points. Due to strong positive momentum, the stock ended at $167.79, which is also near the day’s high of $168.07. The stock began the session at $163.75 and the volume stood at 11,23,622 shares. The 52-week high of the shares is $186.88 and the 52 week low is $119.37. The company has a current market capitalization of $24,548 M and it has 14,63,00,000 shares in outstanding.
Illumina(ILMN) last announced its earnings results on Nov 1, 2016 for Fiscal Year 2016 and Q3.Company reported revenue of $607.14M. Analysts had an estimated revenue of $628.18M. Earnings per share were $0.97. The reported EPS was above estimates by $0.06 or 6.59%. Analysts had estimated an EPS of $0.91.
Several Insider Transactions has been reported to the SEC. On Mar 10, 2017, A Blaine Bowman (director) sold 3,000 shares at $165.12 per share price.Also, On Feb 21, 2017, Daniel Bradbury (director) sold 600 shares at $162.79 per share price.On Feb 15, 2017, Omead Ostadan (EVP Ops, Products, Strategy) sold 2,173 shares at $163.10 per share price, according to the Form-4 filing with the securities and exchange commission.
Illumina Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms reagent kits and scanning equipment. Its customers include genomic research centers academic institutions government laboratories hospitals and reference laboratories pharmaceutical biotechnology agrigenomics commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research including de novo sequencing genetic variation analysis epigenetics and targeted screening among others. It also provides products and services for other life sciences applied markets such as agrigenomics. It also offers Clarity Run Manager Clarity LIMS Silver and Clarity LIMS Gold.